For an adult patient requiring a β‑blocker for hypertension, chronic heart failure, or stable angina, which is preferred—bisoprolol or metoprolol succinate—considering comorbidities such as chronic obstructive pulmonary disease or renal impairment?

Bisoprolol vs Metoprolol Succinate

For most patients requiring a β-blocker for hypertension, chronic heart failure, or stable angina, bisoprolol and metoprolol succinate are therapeutically equivalent in terms of mortality and morbidity outcomes, but bisoprolol is specifically preferred when chronic obstructive pulmonary disease (COPD) is present due to its superior β1-selectivity. 1

Heart Failure with Reduced Ejection Fraction

Both bisoprolol and metoprolol succinate have equivalent mortality benefits in heart failure with reduced ejection fraction (HFrEF). The evidence base for β-blockers in heart failure has been established specifically for bisoprolol, metoprolol succinate, carvedilol, and nebivolol—these agents demonstrate similar effects on heart failure mortality. 2

• The NICE guidelines explicitly state that selective β-blockers such as bisoprolol and metoprolol succinate used in randomized clinical trials have a similar effect on heart failure mortality 2
• Both agents reduce morbidity and increase survival in patients with left ventricular systolic dysfunction 2
• If a patient is already on a different β-blocker for a comorbid condition and develops heart failure, therapy should be switched to one of these evidence-based agents 2

The key distinction is that the lower mortality previously observed with carvedilol versus metoprolol was attributed to the use of short-acting metoprolol tartrate in that trial—not the sustained-release metoprolol succinate formulation 2.

Chronic Obstructive Pulmonary Disease

Bisoprolol is the only β-blocker explicitly stated as not contraindicated in COPD due to its high β1-selectivity. 1

• The 2018 expert consensus document in Nature Reviews Cardiology specifically identifies bisoprolol as having the highest β1-selectivity among β-blockers 1
• β-selective blockers are generally well-tolerated in COPD patients and may paradoxically improve survival and bronchial responsiveness 1
• Research evidence confirms that in patients with heart failure and COPD, forced expiratory volume in 1 second (FEV1) was highest with bisoprolol compared to metoprolol or carvedilol 3
• A 2003 study in patients with isolated systolic hypertension and COPD found that external respiratory function remained unchanged with bisoprolol, while atenolol and metoprolol caused significant deterioration 4

Important caveat: Coexistence of asthma or COPD with positive bronchoreactivity remains a clear contraindication to all β-blockers 1.

Hypertension and Stable Angina

For uncomplicated hypertension or stable angina without heart failure or COPD, both agents are equivalent:

• Both are effective first-line options for hypertension 5
• For stable angina pectoris without previous heart failure or myocardial infarction, either β-blocker can be used as initial therapy 5
• The 2020 Hypertension Canada guidelines recommend bisoprolol specifically for resistant hypertension as add-on therapy 5

Renal Impairment

Neither bisoprolol nor metoprolol succinate has specific contraindications in renal impairment, unlike ranolazine and trimetazidine which should not be used when GFR <30 mL/min/1.73 m² 1. Both β-blockers can be used safely in chronic kidney disease, though monitoring is prudent.

Bisoprolol has dual hepatic and renal elimination pathways, potentially offering an advantage in severe renal dysfunction, though this is not explicitly stated in the guidelines.

Practical Prescribing Algorithm

Choose bisoprolol if:

• COPD is present (any severity)
• Resistant hypertension requiring add-on therapy
• Patient preference for once-daily dosing

Choose metoprolol succinate if:

• Post-myocardial infarction (both ACE inhibitor and β-blocker recommended; metoprolol succinate has specific FDA indication) 5, 6
• Patient already stable on metoprolol succinate
• Cost considerations favor metoprolol

Either agent is appropriate for:

• HFrEF (NYHA Class II-III)
• Uncomplicated hypertension
• Stable angina without COPD

Titration Principles

Both agents should be initiated using a "start-low, go-slow" approach 2:

• Monitor heart rate, blood pressure, and clinical status after each dose titration
• Avoid symptomatic bradycardia and hypotension
• Target doses: bisoprolol 10 mg once daily; metoprolol succinate 200 mg once daily 7, 8

Common Pitfall

Do not abruptly discontinue either β-blocker, particularly in patients with ischemic heart disease, as this can precipitate exacerbations of angina pectoris or myocardial infarction 6. Taper gradually over 1-2 weeks when discontinuation is necessary.